China Universal Asset Management Co. Ltd. Purchases Shares of 11,619 Abivax SA Sponsored ADR $ABVX

Key Points

• China Universal Asset Management acquired a new stake of 11,619 shares (~$1.57M) in Abivax in Q4, and other institutions including Jefferies, Federated Hermes, Atika and Tudor also built positions, leaving institutional ownership at about 47.91%.
• Abivax opened at $114.56, has a market cap of $9.08B and a one‑year range of $5.59–$148.83; the company reported Q4 EPS of –$1.20 on $0.52M revenue, and analysts hold a consensus "Moderate Buy" rating with a $137.15 price target.

China Universal Asset Management Co. Ltd. acquired a new stake in Abivax SA Sponsored ADR (NASDAQ:ABVX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 11,619 shares of the company's stock, valued at approximately $1,567,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Jefferies Financial Group Inc. bought a new position in Abivax during the third quarter worth about $38,827,000. Federated Hermes Inc. bought a new stake in shares of Abivax in the 3rd quarter valued at approximately $8,448,000. Persistent Asset Partners Ltd bought a new stake in shares of Abivax in the 3rd quarter valued at approximately $815,000. Atika Capital Management LLC acquired a new position in shares of Abivax in the 3rd quarter worth approximately $5,858,000. Finally, Tudor Investment Corp ET AL acquired a new position in shares of Abivax in the 3rd quarter worth approximately $2,792,000. 47.91% of the stock is owned by institutional investors.

Abivax Price Performance

NASDAQ ABVX opened at $114.56 on Friday. The stock's 50 day simple moving average is $118.27 and its 200 day simple moving average is $115.69. Abivax SA Sponsored ADR has a one year low of $5.59 and a one year high of $148.83. The firm has a market cap of $9.08 billion, a PE ratio of -21.33 and a beta of 1.68.

Abivax (NASDAQ:ABVX - Get Free Report) last issued its quarterly earnings data on Saturday, February 14th. The company reported ($1.20) earnings per share (EPS) for the quarter. The business had revenue of $0.52 million during the quarter. As a group, equities analysts expect that Abivax SA Sponsored ADR will post -3.84 earnings per share for the current year.

Analyst Upgrades and Downgrades

ABVX has been the topic of several recent analyst reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Abivax in a research note on Monday. BTIG Research reissued a "buy" rating and set a $150.00 price objective on shares of Abivax in a report on Wednesday, February 25th. Citigroup restated a "market outperform" rating on shares of Abivax in a research note on Thursday, January 8th. Barclays upped their target price on shares of Abivax from $142.00 to $148.00 and gave the stock an "overweight" rating in a report on Tuesday, March 24th. Finally, Wedbush initiated coverage on shares of Abivax in a research report on Tuesday, February 24th. They set an "outperform" rating and a $110.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Abivax has an average rating of "Moderate Buy" and a consensus price target of $137.15.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.

Want to see what other hedge funds are holding ABVX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abivax SA Sponsored ADR (NASDAQ:ABVX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.